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as an allocation tool for patients with end-stage liver disease, nor
as a tool to predict outcome in acute liver failure (ALF). However,
to date, the MELD score in its current form, without adaptation of
the original regression coefﬁcients used in the original Mayo
model, is widely used to allocate grafts for patients with end-
stage liver disease; it was found to predict survival and thus
the need for transplantation better than the previously used
waiting list and Child-Pugh classiﬁcation [3]. In particular, the
low frequency of viral liver diseases in the original Mayo cohort
is contradictory to current observations that the number of trans-
plantations due to HCV cirrhosis is dramatically rising. Thus, it is
questionable whether the original regression calculations reﬂect
the overall patient population with end-stage liver diseases of
the present date. However, UNOS and Eurotransplant make use
of the original formula and the current MELD formula is consid-
ered the gold standard in organ allocation, worldwide.
Furthermore, several recent publications used the original
Mayo formula to predict survival in ALF and found the MELD to
be superior to previous calculations (i.e. KCC) [4,5]. We observed
that (i) bilirubin values are of no predictive value within the
MELD calculation regarding survival of ALF patients and that
(ii) the circulating CK18 as assessed by M65 ELISA is of good
prognostic value in this cohort. (iii) When we replaced bilirubin
with M65 in the original formula, we found a dramatic improve-
ment of predictive value in our cohort of ALF patients (Fig. 1). The
aim of our study was to identify tools to predict if a particular
patient needs a transplant, or if her/his liver has the capacity to
regenerate spontaneously, a situation which rarely occurs in
chronic liver disease. Therefore, we chose the outcome as an end-
point rather than time to death or transplantation.
We agree with Dr. McPhail that ideally, the development of a
multivariate regression model would improve the quality of the
modiﬁed MELD as well as the original MELD calculations. How-
ever, the available sample size was underpowered for this type
of statistical method; for this reason, we decided to perform these
analyses after a validation period with a larger patient cohort in a
currently initiated prospective study. This is especially important
since we might identify even better predictors, depending on the
different etiologies of ALF in a larger cohort.
At the end, we agree that statistical models are not directly
interchangeable between different diseases and populations, thus
repeated modelling is necessary to improve the validity of a
model, which was also suggested by D. Samuel [6]. We continue
to include data from more patients in order to validate our model
and perform multivariate regression analysis. Due to the fortu-
nately rare disease, a registry of ALF-patients in Europe would
enhance the available patient numbers and thus help to further
improve our understanding and management of these patients.
Disclosure
CJ, LPB and AC have no conﬂicts of interest and are supported by
the DFG, Germany.
References
[1] Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to
predict poor survival in patients undergoing transjugular intrahepatic
portosystemic shunts. Hepatology 2000;31:864–871.
[2] Bechmann LP, Jochum C, Kocabayoglu P, Sowa JP, Kassalik M, Gieseler RK, et al.
Cytokeratin 18-based modiﬁcation of the MELD score improves prediction of
spontaneous survival after acute liver injury. J Hepatol 2010;53:
639–647.
[3] Cholongitas E, Germani G, Burroughs AK. Prioritization for liver transplanta-
tion. Nat Rev Gastroenterol Hepatol 2010;7:659–668.
[4] Yantorno SE, Kremers WK, Ruf AE, Trentadue JJ, Podesta LG, Villamil FG. MELD
is superior to King’s college and Clichy’s criteria to assess prognosis in
fulminant hepatic failure. Liver Transplant 2007;13:822–828.
[5] Dhiman RK, Jain S, Maheshwari U, Bhalla A, Sharma N, Ahluwalia J, et al. Early
indicators of prognosis in fulminant hepatic failure: an assessment of the
model for end-stage liver disease (MELD) and King’s College Hospital criteria.
Liver Transplant 2007;13:814–821.
[6] Samuel D, Ichai P. Prognosis indicator in acute liver failure: Is there a place for
cell death markers? J Hepatol 2010;53:593–595.
Christoph Jochum
Lars Bechmann
Ali Canbay⇑
University Hospital Essen, Dept. of Gastroenterolgy and Hepatology,
Hufelandstr. 55, 45122 Essen, NRW, Germany
⇑ Tel.: +49 20172384713; fax: +49 2017235719.
E-mail address: ali.canbay@uni-due.de (A. Canbay)
0.0 0.2 0.4 0.6 0.8 1.0
0
0.2
0.4
0.6
0.8
1.0
1 - Specificity
Diagonal segments are produced by ties
Se
ns
iti
vi
ty
Source of the Curve
MELD
ROC curves
MMELD
Reference line
Fig. 1. Head-to-head comparison of ROC curves for MELD vs. modiﬁed MELD
on admission. We found a better prognostic value of the modiﬁed MELD
(MMELD, straight line) compared to the MELD score (dotted line) in patients
admitted for ALF (n = 68). When we computed MMELD and MELD head to head,
the AUC of the ROC curve was higher in MMELD.
JOURNAL OF HEPATOLOGYPropofol in patients with cirrhosis and minimal
hepatic encephalopathyTo the Editor:
We read with interest the article by Khamaysi et al. [1] in
which it was concluded that sedation with propofol does notJournal of Hepatology 2011exacerbate subclinical hepatic encephalopathy (SHE), and allows
a shorter recovery time and a shorter time to discharge than
midazolam.vol. 54 j 1320–1326 1321
Letters to the Editor
We wish to highlight that based on a single abnormal psy-
chometry test (NCT-A), they labeled 95% of their patients as hav-
ing minimal hepatic encephalopathy (MHE); however, according
to Ferenci et al. [2] two or more abnormal psychometric tests are
needed to label patients with MHE which is a better terminology
than SHE. Although it is not clear to us which sedation (propofol/
midazolam) was given to them, they took 30 controls with no
liver disease and found no deterioration/improvement in NCT-A
tests; looking at the induction and recovery time it seems that
they were given propofol. The primary result of the study that
midazolam prolongs the psychometry tests in cirrhotics would
be better appreciated if the effect of midazolam on psychometric
tests was assessed in the control arm. The second end point of the
study was that patients can be discharged early if an endoscopy
was done under propofol. At what time patients can be dis-
charged after endoscopy is a big question that has not been well
addressed. The mean time of recovery was higher in the midazo-
lam group compared to propofol (11.5 ± 5.0 vs 4.1 ± 1.9 min,
p <0.001); the parameters taken to discharge the patients at
110.0 ± 42.0 min in the midazolam group and 38.0 ± 9.0 min in
the propofol group was not clear. Some objective parameters
before discharge like Post-Anesthetic Discharge Scoring System
or the Aldrete scoring system should be used. The authors of this
study planned to repeat a NCT-A after 1 h in sedated patients;
however, this statement is contradicted by the fact that the mean
time to discharge in the propofol group was 38.0 ± 9.0 min. We
are also confused about what happened to the patients in the
midazolam group who had an increased NCT-A after endoscopy.
It would be important to know whether during follow up of
24–48 h in these patients there was any side effects related to
sedation in either group.
Previous studies have shown that a learning effect is associ-
ated with psychometry tests [3,4]. Consequently, a deterioration
in the performance of patients in these tests would be difﬁcult
to pick up by repeating these tests. Tests like critical ﬂicker fre-
quency or inhibitory control test would be better adapted for this
assessment. In addition, they observed transient hypoxemia
(<90% saturation) in four patients (two in each group) but none
in controls, implying that cirrhotic patients are more prone to
transient hypoxemia after sedation. From the study, it was not
clear whether patients under sedation received prophylactic oxy-
gen; moreover, the patients’ American Society of Anesthesiolo-
gists Physical Status (ASA) score was also not provided, as it
might affect the outcome of psychometry tests and recovery time.
In our experience (unpublished data) of more than 1000
endoscopies (both in cirrhotics and non-cirrhotics) performedSub-clinical hepatic encephalo
not aggravated by sedation
to midazolam: A random
This is a reply to the Letter to the Editor by Sharma et al.
Thank you very much for the interesting comments by Dr.
Sharma et al. We agree that hepatic encephalopathy is better
deﬁned by multiple psychometric tests than a single psychomet-
ric test, but NCT-A can still reliably detect minimal degrees of
hepatic encephalopathy. Moreover, NCT is considered the stan-
1322 Journal of Hepatology 201over a year under propofol sedation (Modiﬁed Observer’s Assess-
ment of Alertness/Sedation Scale score 1), we agree with the
results by Khamaysi et al. that propofol sedation is safe in per-
forming upper gastrointestinal endoscopy in cirrhotic patients
when given by anesthetist. In fact, all of our patients could be dis-
charged at 2 h post-endoscopy. However, two or more psychom-
etry tests/CFF/ICT need to be performed to evaluate cognitive
function before and after endoscopy, as well as a longer follow
up to ensure that propofol does not exacerbate MHE.
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dard in this area because of its sensitivity, ease of application,
and quantitative aspect [1].We agree that minimal hepatic
encephalopathy (MHE) may be a more precise terminology than
sub-clinical hepatic encephalopathy (SHE).
In our study, patients in the control group were given midaz-
olam sedation and were discharged from the endoscopy unit as
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